Mauro D'Amato

The ultimate goal of my research is a translational application for improved therapeutic precision in gastroenterology. My team combine genomic, computational and pre-clinical expertise to identify causative genes and pathogenetic mechanisms leading to gastrointestinal (GI) disease and/or deleterious alterations of the human gut microbiome. The druggable genome and nutrigenetics are also new research lines of high interest, in relation to “gut health” and the possibility to treat GI symptoms, or therapeutically modulate the composition of the intestinal microbiota.
We take advantage of an extremely large network of international collaboration (>60 research groups and institutions across EU, USA and Australasia) for large biobank-scale and multi-centre investigations, often using complex and heterogenous data from different sources. We currently lead several projects that aim to identify GI disease risk via coordinated analytical efforts in more than 1 million people across international biobanks and cohorts.
Our research also contributes to the activities of multiple consortia including the bellygenes inititative I coordinate on the genetics of IBS.